QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.105.086173v1 314/3/1226    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Roberts, J. C. Articles by Fairbanks, C. A. Search for Related Content PubMed PubMed Citation Articles by Roberts, J. C. Articles by Fairbanks, C. A.

NEUROPHARMACOLOGY

Pharmacodynamic and Pharmacokinetic Studies of Agmatine after Spinal Administration in the Mouse

Departments of Pharmaceutics (J.C.R., B.M.G., C.A.F.), Pharmacology (B.M.G., K.F.K., C.A.F.), and Neuroscience (K.F.K., C.A.F.), and Center for Pain Research (J.C.R., K.F.K., C.A.F.), University of Minnesota, Minneapolis, Minnesota

Agmatine is an endogenous decarboxylation product of arginine that has been previously shown to antagonize the N-methyl-D-aspartate (NMDA) receptor and inhibit nitric-oxide synthase. Many neuropharmacological studies have shown that exogenous administration of agmatine prevents or reverses biological phenomena dependent on central nervous system glutamatergic systems, including opioid-induced tolerance, opioid self-administration, and chronic pain. However, the central nervous system (CNS) pharmacokinetic profile of agmatine remains minimally defined. The present study determined the spinal cord pharmacokinetics and acute pharmacodynamics of intrathecally administered agmatine in mice. After a single bolus intrathecal injection, agmatine concentrations in spinal cord (cervical, thoracic, and lumbosacral) tissue and serum were quantified by an isocratic high-performance liquid chromatography fluorescence detection system. Agmatine persisted at near maximum concentrations in all levels of the spinal cord for several hours with a half-life of approximately 12 h. Initial agmatine concentrations in serum were 10% those in CNS. However, the serum half-life was less than 10 min after intrathecal injection of agmatine, consistent with previous preliminary pharmacokinetic reports of systemically administered agmatine. The pharmacodynamic response to agmatine in the NMDA-nociceptive behavior and thermal hyperalgesia tests was assessed. Whereas MK-801 (dizocilpine maleate) inhibits these two responses with equal potency, agmatine inhibits the thermal hyperalgesia with significantly increased potency compared with the nociceptive behavior, suggesting two sites of action. In contrast to the pharmacokinetic results, the agmatine inhibition of both behaviors had a duration of only 10 to 30 min. Collectively, these results suggest the existence of a currently undefined agmatinergic extracellular clearance process in spinal cord.

Address correspondence to: Dr. Carolyn A. Fairbanks, Department of Pharmaceutics, University of Minnesota, 9-177 Weaver Densford Hall, 308 Harvard St. S.E., Minneapolis, MN 55455. E-mail: carfair{at}umn.edu

This article has been cited by other articles:

				C. Courteix, A.-M. Privat, T. Pelissier, A. Hernandez, A. Eschalier, and J. Fialip Agmatine Induces Antihyperalgesic Effects in Diabetic Rats and a Superadditive Interaction with R( )-3-(2-Carboxypiperazine-4-yl)-propyl-1-phosphonic Acid, a N-Methyl-D-aspartate-Receptor Antagonist J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1237 - 1245. [Abstract] [Full Text] [PDF]